Opus Genetics
Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.
$3.81
After-hours close+0.10 (+2.70%)
At close$3.71(−3.64%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 14.40%
Shares outstanding 82.57M · Float 34.98M · 42.4% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.99% | 8.83M | 13G | May 15, 2026 ↗ |
| Caligan Partners LP | 8.50% | 6.08M | 13G | May 15, 2026 ↗ |
| Adage Capital Management, L.P. | 8.47% | 6.03M | 13G | May 13, 2026 ↗ |
| Balyasny Asset Management L.P. | 7.18% | 5.11M | 13G | May 15, 2026 ↗ |
| Nantahala Capital Management, LLC | 6.51% | 4.84M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | director, other: See Remarks | 3.79M | 4.59% | May 20, 2026 |
| Cam Gallagher | director | 2.10M | 2.54% | Apr 22, 2026 |
| George Magrath | director, officer: Chief Executive Officer | 1.73M | 2.10% | Jul 27, 2026 |
| Benjamin R. Yerxa | director, officer: President | 704.1K | 0.85% | Jul 27, 2026 |
| Robert E. Gagnon | officer: Chief Financial Officer | 584.4K | 0.71% | Jul 27, 2026 |
| Ashwath Jayagopal | officer: Chief Scientific & Dev. Ofc. | 509.2K | 0.62% | Apr 27, 2026 |
| Richard J. Rodgers | director | 343.0K | 0.42% | Apr 22, 2026 |
| Sean Ainsworth | director | 321.7K | 0.39% | Apr 22, 2026 |
| James S. J. Manuso | director | 317.3K | 0.38% | Apr 22, 2026 |
| Joseph K. Schachle | officer: Chief Operating Officer | 291.4K | 0.35% | Jul 27, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 23, 2026 | Robert E. Gagnonofficer: Chief Financial Officer | Sale | 7,783 | $2.95 | 584,375 |
| Jul 23, 2026 | George Magrathdirector, officer: Chief Executive Officer | Sale | 9,475 | $2.95 | 1,731,869 |
| Jul 23, 2026 | Joseph K. Schachleofficer: Chief Operating Officer | Sale | 4,644 | $2.94 | 291,440 |
| Jul 23, 2026 | Benjamin R. Yerxadirector, officer: President | Sale | 7,429 | $2.97 | 704,106 |
| May 18, 2026 | Foundation Fighting Blindness Retinal Degeneration Funddirector, other: See Remarks | Sale | 1,700,000 | $4.35 | 3,792,171 |
| Apr 23, 2026 | Robert E. Gagnonofficer: Chief Financial Officer | Sale | 7,842 | $5.18 | 592,158 |
| Apr 23, 2026 | Ashwath Jayagopalofficer: Chief Scientific & Dev. Ofc. | Sale | 7,542 | $5.19 | 509,233 |
| Apr 23, 2026 | George Magrathdirector, officer: Chief Executive Officer | Sale | 9,511 | $5.22 | 1,741,344 |
| Apr 23, 2026 | Rabourn Amy Zarembaofficer: Head of Fin. Quality Assurance | Sale | 1,641 | $5.20 | 188,671 |
| Apr 23, 2026 | Joseph K. Schachleofficer: Chief Operating Officer | Sale | 4,697 | $5.22 | 296,084 |
CongressHouse and Senate disclosures
Not reported.